As shown in Figures 6A–D, the MTT assay and trypan blue staining assay results showed that the inhibiting effects of ANXA6 ablation on cell proliferation and viability in PTX-treated PR-BC cells were reversed by overexpressing YAP1. Here, ANXA6 is linked to breast cancer.